References

1. Annas GJ, Grodin MA, eds. Nazi Doctors and the Nuremberg Code: Rights in Human Experiments. Oxford: Oxford University Press, 1992.

2. Hazelgrove J. The old faith and new science: the Nuremberg Code and human experimentation ethics in Britain 1946-1973. Soc Hist Med 2001; 15(1):109-135.

3. Beecher H. Experimentation in man. J Am Med Assoc 1959; 169:461-478.

4. Beecher H. Ethics and clinical research. New Engl J Med 1966; 16:1354-1360.

5. Pappworth MH. Human guinea pigs: a warning. Twentieth Century 1962; 171:67-75.

6. Pappworth MH. Human Guinea Pigs: Experimentation on Man. London: Routledge & Kegan Paul, 1967.

7. http://www.wma.net/e/policy/17-c_e.html

8. Jones JH. Bad Blood: The Tuskegee Syphilis Experiment. New York: Free Press, 1981.

9. Rothman DJ. Strangers at the Bedside: A History of How Law and Bioethics Transformed Medical Decision Making. New York: Basic Books, 1993.

10. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 1st ed. New York: Oxford University Press, 1979.

11. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 5th ed. New York: Oxford University Press, 2001.

12. Wolpe PR. The triumph of autonomy in American bioethics: a sociological view. In: DeVries R, Subedi J, eds. Bioethics and Society: Constructing the Ethical Enterprise. Upper Saddle River, NJ: Prentice Hall, 1998:38-39.

13. Benatar SR. Just health care beyond individualism: challenges for North American bioethics. Cambridge Q Health Care Ethic 1997; 6:397-415.

14. Richards C, Dingwall R, Watson A. Should NHS patients be allowed to contribute extra money to their care? A debate from the Nottingham ethics of clinical practice committee. Brit Med J 2001; 323:563-565.

15. Rothstein MA, Epps PG. Ethical & legal implications of pharmacogenomics. Nat Rev Genet 2001; 2:228-231.

16. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000b; 405:857-865.

17. Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev: Drug Discov 2002; 1:300-308.

18. Robertson JA, Brody B, Buchannan A, Kahn J, McPherson E. Pharmacogenetic challenges for the health care system. Health Affairs 2002; 21(4):155-167.

19. Lichter JB, Kurth JH. The impact of pharmacogenomics on the future of healthcare. Curr Opin Biotechnol 1997; 8:692-695.

20. Clarke A, English V, Harris H, Wells F. Report on ethical considerations. Int J Pharmceut Med 2001; 15:89-94.

21. Robertson JA. Consent and privacy in pharmacogenetic testing. Nat Genet 2002; 28(3):207-209.

22. Holtzman NA, Watson MS. Promoting Safe and Effective Genetic Testing in the United States. The National Human Genome Research Institute, Bethesda, MD, 1997.

23. Human Genetics Commission. Inside information: balancing interests in the use of personal genetic information. London, Human Genetics Commission, 2002.

24. Mastroianni AC, Faden R, Federman D. Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies. Institute of Medicine. Washington, DC: National Academy Press, 1994.

25. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 2003; 348(6):553-556.

26. O'Kane DJ, Weinshilboum RM, Moyer TP. Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics 2003; 4(1):1-4.

27. Danzon P, Towse A. The economics of gene therapy and of pharmacogenetics. Value in Health 2002; 5(1):5-13.

28. Medawar C. Power and Dependence: Social Audit on the Safety of Medicines. London: Social Audit, 1992.

29. Kuivenhoven J. The role of a common variant of the CETP gene in the progression of coronary arthersclerosis. N Engl J Med 1998; 338(2):86-93.

30. Lindpainter K, Foot E, Caulfield M, Hall I. Pharmacogenetics: focus on pharmacodynamics. Int J Pharmaceut Med 2001; 15:74-82.

31. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000a; 355:1358-1361.

32. Martin P, Frost R. Regulating the commercial development of genetic testing in the UK: problems, possibilities and practice. Crit Soc Policy 2003; 23(2):186-207.

33. Melzer D, Zimmern R. Genetics and medicalisation. Brit Med J 2002; 324(4):863-864.

34. Xie H-G, Kim RB, Wood AJJ, Stein CM. Ethnic differences in drugs disposition and response. Annu Rev Pharmacol Toxicol 2001; 41:815-850.

35. Satel S. I am a racially profiling doctor. New York Times Magazine. 5-5-2002.

Cure Your Yeast Infection For Good

Cure Your Yeast Infection For Good

The term vaginitis is one that is applied to any inflammation or infection of the vagina, and there are many different conditions that are categorized together under this ‘broad’ heading, including bacterial vaginosis, trichomoniasis and non-infectious vaginitis.

Get My Free Ebook


Post a comment